Huge Study Shows Where Gout Comes From – It's Not What We Thought
Gout is often associated with drinking too much or not eating healthily enough, but research suggests genetics play more of a factor in developing the arthritic condition than previously thought.
A recent study, carried out by an international team of scientists, looked at genetic data collected from 2.6 million people across 13 different cohorts of DNA data. That number included 120,295 people with "prevalent gout".
By comparing the genetic codes of the people with gout against the people without, the team found 377 specific DNA regions where there were variations specific to having the condition – 149 of which hadn't been previously linked to gout.
While lifestyle and environmental factors are certainly still in play, the findings suggest genetics play a major role in determining whether or not someone gets gout – and the researchers think there may be more undiscovered genetic links still to be found, too.
"Gout is a chronic disease with a genetic basis and is not the fault of the sufferer – the myth that gout is caused by lifestyle or diet needs to be busted," said epidemiologist Tony Merriman from the University of Otago in New Zealand, when the study was published last year.
Gout takes hold when there are high levels of uric acid in the blood, which then form sharp crystal needles in the joints. When the body's immune system starts to attack those crystals, it leads to significant pain and discomfort.
Genetics is important in every stage of that process, the researchers suggest. Particularly, it affects the likelihood of the body's immune system attacking the crystals, and in the way uric acid is transported around the body.
Gout can come and go, but there are treatments available – and the authors behind the study think misconceptions can put people off getting those treatments. That's a real problem with cases of the condition rising and rising.
"This widespread myth causes shame in people with gout, making some people more likely to suffer in silence and not go and see the doctor to get a preventive drug that lowers urate in the blood and will prevent their pain," said Merriman.
On top of giving us a better understanding of the causes of gout, the study gives scientists more options to explore when it comes to treatments, particularly in terms of managing the body's immune response to the build up of uric acid. In fact, existing drugs could be repurposed for this job.
There are some limitations to the study: the majority of the data was from people of European ancestry, and some records relied on the self-reporting of gout rather than a clinical diagnosis. Nevertheless, it gives us a much better sense of a health problem that's been afflicting people for centuries.
"We hope that, in time, better and more accessible treatments will become available with the new targets we identified," said Merriman. "Gout deserves more health spend resource and greater prioritization in the health system."
The research has been published in Nature Genetics.
An earlier version of this article was published in November 2024.
Identifying Chemicals in Our Environment Could Help Medicines Work Better
How Well Is Your Gut Working? There's a Grossly Simple Way to Check.
A Shocking Number Still Don't Know The Risk of Taking Aspirin Each Day
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
2 days ago
- Business Upturn
Marksans Pharma's UK subsidiary secures approval for Oxybutynin Hydrochloride oral solution
By Aditya Bhagchandani Published on June 19, 2025, 09:14 IST Marksans Pharma Limited announced today that its wholly owned UK-based subsidiary, Relonchem Limited, has received Marketing Authorization for Oxybutynin Hydrochloride 2.5mg/5ml Oral Solution from the UK's Medicines & Healthcare Products Regulatory Agency (MHRA). The product, used primarily for treating overactive bladder and urinary incontinence, expands Marksans' offering in the urology therapeutic segment and strengthens its European portfolio. The company, headquartered in Mumbai, manufactures and markets generic pharmaceutical formulations globally, with facilities in India, the US, and the UK—approved by regulatory bodies including the USFDA, UKMHRA, and Australia's TGA. 'This approval further reinforces our commitment to expanding our presence in regulated markets through high-quality generic products,' the company said in a press release. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Yahoo
2 days ago
- Yahoo
NHS England chair suggests England can learn from European health schemes
With the 10-year Health Plan on the horizon, the NHS could learn some tricks from France, Germany and the Nordics. At the HLTH Europe conference taking place in Amsterdam, the Netherlands, from 16 to 19 June, NHS England chair Penny Dash highlighted that certain aspects of European health systems could translate well in the NHS. 'I think German payers have got absolutely amazing analytical capabilities and they can do things such as vary payment up and down, dependent on volumes of activity and demand,' said Dash. 'We could do things like that. I would also look at some bits of the French system in terms of digitalisation – there are some good examples there. I would focus on the work in all of the Nordic countries on primary care, as their models of primary care are population health-focused. The Nordic countries spend a significantly lower proportion of their health budget on hospitals than we do.' Dash spotlighted some strengths of the NHS, including genomics, access to data and evidence base. However, she acknowledged that the health system needs to better utilise patient data to advance healthcare. Dash's remarks come amid UK Health Secretary Wes Streeting's announcement to abolish NHS England, with the service set to return to government control. They also precede Streeting's upcoming unveiling of the 10-year Health Plan for the NHS, which will emphasise a move from hospital to community, from analogue to digital systems, and from sickness to prevention. Speaking on the plan, Dash added: 'What we are planning to do and are already doing are very analogous to what other countries are doing. We have looked at the rest of the world and we've asked: 'What are other people doing? What seems to be working? What seems to be having an impact?' Then draw on that. The Secretary of State has been very clear since he was in opposition, talking about the three shifts.' Earlier this month, an additional $29bn was granted to the NHS by Chancellor Rachel Reeves. The following day at the NHS ConfedExpo, Streeting acknowledged this boost as "substantial" but said reform is still essential. "NHS England chair suggests England can learn from European health schemes" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
UPI
2 days ago
- UPI
Supreme Court affirms Tennessee ban on gender-affirming care for youth
Chief Justice of the Supreme Court John Roberts and Justice Elena Kagan attend President Donald Trump's address to a joint session of Congress at the U.S. Capitol in Washington, D.C., on March 4. In his majority opinion, Roberts cited risks associated with providing gender-affirming care to minors. File Pool photo by Win McNamee/UPI | License Photo June 18 (UPI) -- The U.S. Supreme Court ruled 6-3 Wednesday to uphold a Tennessee law that bans gender-affirming care for minors. More than 20 states have similar laws that the court's ruling may impact. The court's ruling fell along ideological lines, with the conservative majority unanimously siding in favor of upholding the law. Tennessee law bars minors from receiving treatments such as gender transition surgery, hormone therapy and puberty blockers. In his majority opinion, Chief Justice John Roberts cited risks associated with providing such treatments to minors, referencing research dating back to 1979 and studies in European countries. "The current standards recognize known risks associated with the provision of sex transition treatments to adolescents, including potential adverse effects on fertility and the possibility that an adolescent will later with to detransition," Roberts wrote. "They further state that there is 'limited data on the optimal timing' of sex transition treatments or 'the long-term physical, psychological and neurodevelopmental outcomes in youth.'" Tennessee passed its law, the "Prohibition on Medical Procedures Performed on Minors Related to Sexual Identity," in 2023. According to Roberts, the Tennessee law is limited in two ways. It does not prohibit the use of puberty blockers or hormone therapy for people who are 18 years old or older. It also does not enact a complete ban on the use of such drugs on minors, for example, to treat early puberty, congenital defects and other conditions. Associate Justice Sonia Sotomayor, in her dissenting opinion, argued that because the law "expressly classified on the basis of sex and transgender status," it should have been considered under intermediate scrutiny, a higher standard than the rational-basis review the conservative justices applied. "By retreating from meaningful judicial review exactly where it matters most, the Court abandons transgender children and their families to political whims," Sotomayor wrote. "Tennessee's ban applies no matter what a minor's parents and doctors think, with no regard for the severity of the minor's mental health conditions or the extent to which treatment is medically necessary for an individual child." Sotomayor recalled the testimonies shared on behalf of the plaintiffs. Several shared concerns about the health and wellbeing of children who are denied gender-affirming care, including a mother who spoke on behalf of her 16-year-old son. Three sets of parents and children who testified are joined in the lawsuit to challenge Tennessee's law. Transgender and nonbinary youth face higher risks of suicide and laws prohibiting gender-affirming care correspond with a 72% increase of suicide attempts, according to a study by the Trevor Project. If you or someone you know is struggling with suicidal thoughts, help is available 24/7. Call or text the 988 Suicide & Crisis Lifeline for free, confidential support. Globally, the International Association for Suicide Prevention has contact information for crisis centers around the world.
